Regulatory Guidelines For Preclinical And Clinical Validation of Traditional Medicines
•Télécharger en tant que PPT, PDF•
13 j'aime•5,318 vues
![REGULATORY GUIDELINES FOR PRECLINICAL AND CLINICAL VALIDATION OF TRADITIONAL MEDICINES Dr. Basavaraj K. Nanjawade Associate Professor of Pharmaceutics Department of Pharmacology JN Medical College Belgaum-10 e-mail: [email_address] BY](https://image.slidesharecdn.com/regulatory-guidelines-for-preclinical-and-clinical-validation-of-1224582232069080-8/85/Regulatory-Guidelines-For-Preclinical-And-Clinical-Validation-of-Traditional-Medicines-1-320.jpg)
![Traditional Medicine ,[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommandé
Recommandé
Contenu connexe
Tendances
Tendances (20)
En vedette
En vedette (20)
Similaire à Regulatory Guidelines For Preclinical And Clinical Validation of Traditional Medicines
Similaire à Regulatory Guidelines For Preclinical And Clinical Validation of Traditional Medicines (20)
Plus de Prof. Dr. Basavaraj Nanjwade
Plus de Prof. Dr. Basavaraj Nanjwade (20)
Dernier
Dernier (20)
Regulatory Guidelines For Preclinical And Clinical Validation of Traditional Medicines
- 1. REGULATORY GUIDELINES FOR PRECLINICAL AND CLINICAL VALIDATION OF TRADITIONAL MEDICINES Dr. Basavaraj K. Nanjawade Associate Professor of Pharmaceutics Department of Pharmacology JN Medical College Belgaum-10 e-mail: [email_address] BY
- 14. Regulatory Approaches FOR MARKETING BOTANICAL DRUG PRODUCTS
- 15. INFORMATION TO BE PROVIDED IN AN IND FOR A BOTANICAL DRUG IND for a Botanical Drug Product General principles; format and contents (slid No. 16) Initial clinical trial of a marketed botanical product with no known safety issues (Slid No. 17) Initial clinical trial of a nonmarketed botanical product or marketed botanical product with known safety issues (Slid No. 19) Expanded clinical Trial of any botanical product (Slid No. 22) Documentation of use limited CMC information; previous human experience may be sufficient to support safety More documentation of use and more CMC information (Slid No. 17) Same documentation of use but more detailed CMC information; standard nonclinical toxicology studies may be needed (Slid 19) Is the product a traditional preparation? Previous human experience may be sufficient to support safety (Slid. No 19) If the product is marketed only outside the U.S. additional CMC and nonclinical safety information may be needed (Slid. No. 17) Additional nonclinical safety information may be needed (Slid No. 19) No Yes
- 26. The New Drug Development Process
- 28. Traditional IND
- 34. Conclusions of Exploratory IND
- 35. Conclusions of Exploratory IND
- 36. NDA Process
- 38. OTC Drug Monograph Process
- 39. THANK YOU..... e-mail: [email_address]